15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.

A Single-blind, Randomised, Placebo-controlled, 15 Day Repeated-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SB-649868 and Its Interaction With the CYP3A4 Isoenzyme in Healthy Male Subjects.

Subjects will be screened within 28 days, Simvastatin dose and single SB-649868 dose 10 and 7 days prior to repeat dosing respectively, 15 days SB-649868 repeat dosing with safety and cognition function tests.

Study Overview

• Status: Completed
• Conditions: Sleep Initiation and Maintenance Disorders
• Intervention / Treatment: Drug: SB-649868; Drug: Placebo; Drug: Simvastatin

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Phase 1

Contacts and Locations

Study Locations

• Germany
  • Berlin, Germany, 14050
    • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Healthy adult male subjects aged between 18 and 65 years of age inclusive.
• Body weight =50 kg and BMI within the range 18.5-29.9 kg/m2 inclusive.
• Healthy as judged by responsible physician. No clinically significant abnormality identified on the medical or laboratory evaluation and 12-lead ECG. A subject with a clinical abnormality or laboratory parameters outside the reference range for this age group may be included only if the Investigator and the Medical Monitor considers that the finding will not introduce additional risk factors and will not interfere with the study procedures.
• Subjects will have blood pressure measurements within the normal range for healthy volunteers.

Exclusion Criteria:

• The subject has a positive pre-study urine drug/ alcohol urine screen.
• A positive pre-study Hepatitis B surface antigen, Hepatitis C antibody, or HIV 1/2 result at the screening visit.
• Abuse of alcohol defined as an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units.
• Subject complains of sleep disturbances and/ or is receiving treatment for sleep disorders.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: SINGLE_GROUP

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Cohort 1; Subjects in Cohort 1 will be randomized to receive 5 milligram (mg) of SB-649868 or Placebo along with 10 mg of simvastatin.	Drug: SB-649868; Subjects will receive SB-649868 5 mg, 25 mg tablets orally 1 hour prior to simvastatin administration.; Drug: Placebo; Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.; Drug: Simvastatin; Subjects will receive Simvastatin 10 mg tablets orally.
EXPERIMENTAL: Cohort 2; Subjects in Cohort 2 will be randomized to receive two or three times higher than the starting dose of SB-649868 or Placebo along with 10 mg of simvastatin.	Drug: SB-649868; Subjects will receive SB-649868 5 mg, 25 mg tablets orally 1 hour prior to simvastatin administration.; Drug: Placebo; Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.; Drug: Simvastatin; Subjects will receive Simvastatin 10 mg tablets orally.
EXPERIMENTAL: Cohort 3; Subjects in Cohort 3 will be randomized to dose higher than that administered in Cohort 2 of SB-649868 or Placebo along with 10 mg of simvastatin.	Drug: SB-649868; Subjects will receive SB-649868 5 mg, 25 mg tablets orally 1 hour prior to simvastatin administration.; Drug: Placebo; Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.; Drug: Simvastatin; Subjects will receive Simvastatin 10 mg tablets orally.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
-AE, Lab values and cardiovascular monitoring after the SD and 14 days RD period (15 days)	after the SD and 14 days RD period (15 days)
- SB649868 levels on days -7, 1, 4, 7 and 14 (pre-dose and post-dose)	on days -7, 1, 4, 7 and 14 (pre-dose and post-dose)
- Simvastatine and Beta-idroxy-simvastatine levels on days -10,1,4,7 and 15	on days -10,1,4,7 and 15

Secondary Outcome Measures

Outcome Measure	Time Frame
Cognitive functions, sleep profile and appetite assessment on days -7, 7 and 14.	on days -7, 7 and 14.

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 18, 2007
• Primary Completion (ACTUAL): August 4, 2007
• Study Completion (ACTUAL): August 4, 2007

Study Registration Dates

• First Submitted: June 29, 2007
• First Submitted That Met QC Criteria: June 29, 2007
• First Posted (ESTIMATE): July 3, 2007

Study Record Updates

• Last Update Posted (ACTUAL): August 8, 2017
• Last Update Submitted That Met QC Criteria: August 5, 2017
• Last Verified: August 1, 2017

More Information

Terms related to this study

• Keywords: Simvastatin; SB-649868,; Repeated dose,
• Additional Relevant MeSH Terms: Mental Disorders; Nervous System Diseases; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Sleep Initiation and Maintenance Disorders; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimetabolites; Anticholesteremic Agents; Hypolipidemic Agents; Lipid Regulating Agents; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin
• Other Study ID Numbers: OXS104092